Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: A case series

Amyloid

Volumn 21, Issue 3, 2014, Pages 149-153

  Lee, Steve Y ^a   Sanchorawala, Vaishali ^a   Seldin, David C ^a   Mark Sloan, J ^a   Andrea, Nancy ^a   Quillen, Karen ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Amyloidosis; Autologous; Heart failure; Plerixafor (JM 3100); Stem cells; Transplantation

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR; ALKYLATING AGENT; HETEROCYCLIC COMPOUND; MELPHALAN;

ADULT; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HEART TRANSPLANTATION; HUMAN; LIGHT CHAIN; MALE; MIDDLE AGED; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL MOBILIZATION; AUTOTRANSPLANTATION; CASE REPORT; COMPLICATION; DRUG EFFECTS; GRAFT SURVIVAL; HEART FAILURE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; PROCEDURES; REMISSION;

AMYLOIDOSIS; ANTINEOPLASTIC AGENTS, ALKYLATING; FEMALE; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEART FAILURE; HEART TRANSPLANTATION; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MELPHALAN; MIDDLE AGED; REMISSION INDUCTION; TRANSPLANTATION, AUTOLOGOUS;

EID: 84906281394     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2014.900486     Document Type: Article

References (23)

1. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.
2. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011;118: 4346-52.
3. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005;112:2047-60. (Pubitemid 41377426)
4. Meier-Ewert HK, Sanchorawala V, Berk JL, Ruberg FL. Cardiac amyloidosis: evolving approach to diagnosis and management. Curr Treat Options Cardiovasc Med 2011;13:528-42.
5. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, McConnell JP, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004;104:1881-7. (Pubitemid 39202301)
6. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, Obici L, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006;107:3854-8. (Pubitemid 43726787)
7. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schönland S, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541-9.
8. Girnius S, Seldin DC, Cibeira MT, Sanchorawala V. New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with highdose melphalan and autologous stem-cell transplantation. J Clin Oncol 2013;31:2749-50.
9. Tsai SB, Seldin DC, Quillen K, Berk JL, Ruberg FL, Meier-Ewert H, Sloan JM, et al. High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. Blood 2012;120:4445-6.
10. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007;357: 1083-93. (Pubitemid 47443213)
11. Shinohara K. Systemic capillary leak syndrome caused by granulocyte colony-stimulating factor. Intern Med (Japan) 2011; 50:2259.
12. Roy V. Autologous stem cell transplant for AL amyloidosis. Bone Marrow Res 2012;2012:238961.
13. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002;99:4276-82. (Pubitemid 34627192)
14. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009;113:5720-6.
15. Duarte RF, Shaw BE, Marín P, Kottaridis P, Ortiz M, Morante C, Delgado J, et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2011;46:52-8.
16. Dey BR, Chung SS, Spitzer TR, Zheng H, Macgillivray TE, Seldin DC, McAfee S, et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem cell transplantation for AL amyloidosis and heart failure. Transplantation 2010;90: 905-11.
17. Quillen K, Seldin DC, Finn KT, Sanchorawala V. A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis. Bone Marrow Transplant 2011;46:976-80.
18. To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood 2011;118:4530-40.
19. De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009;77: 1655-64.
20. U.S. Food and Drug Administration. Highlights of prescribing information: Mozobil (plerixafor injection), solution for subcutaneous use. MedWatch The FDA Safety Information and Adverse Event Reporting Program. 2008. [updated 2013 Jun; cited 2013 Aug 27]. Available from: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2013/022311s013lbl.pdf
21. Oran B, Malek K, Sanchorawala V, Wright DG, Quillen K, Finn KT, La Valley M, et al. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 2005;35: 567-75. (Pubitemid 40450454)
22. Dunn D, Vikas P, Jagasia M, Savani BN. Plerixafor in AL amyloidosis: improved graft composition and faster lymphocyte recovery after auto-SCT in patient with end-stage renal-disease. Bone Marrow Transplant 2012;47:1136-7.
23. Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ, Langston A, et al. Effectiveness and cost analysis of ''just-in-time'' salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 2011;51: 2175-82.